Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.59 |
| ▸ | ITGAV | P06756 | 12/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241017 | 1.00 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7379400 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7379407 | 0.91 | ITGB3 (0.58) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7377253 | 0.90 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7377256 | 0.90 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7376058 | 0.90 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7376050 | 0.90 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7377263 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7377087 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7377094 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | claimed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
| EP-1227847-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND ALPHAVBETA3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-07 | — | — | EP | disclosed |
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| WO-2001024827-A2 | INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGA2B 10/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGA2B 12/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.